Skip to search formSkip to main contentSkip to account menu

CHOP protocol-cyclophosphamide/doxorubicin/prednisone/vincristine

Known as: CTX/DOX/PRED/VCR, ACOP, cyclophosphamide, doxorubicin, prednisone, and vincristine protocol 
National Institutes of Health

Related topics

Related topics

15 relations

Broader (5)

Antineoplastic Combined Chemotherapy ProtocolsCyclophosphamideCyclophosphamide/Doxorubicin/Etoposide/Prednisone/VincristineDoxorubicin

Narrower (3)

CAUP protocolCHOP-14 protocolCHOP-21 protocol
CDE protocol-cyclophosphamide/doxorubicin/etoposideCHOP regimenDoxorubicin HydrochloridePrednisone

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study
Highly Cited
2012
Highly Cited
2012
Treatment of older patients with mantle-cell lymphoma.
BACKGROUND The long-term prognosis for older patients with mantle-cell lymphoma is poor. Chemoimmunotherapy results in low rates… 
Highly Cited
2011
Highly Cited
2011
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International…
Highly Cited
2010
Highly Cited
2010
Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.
To evaluate outcome and prognosis of patients with T-cell lymphoma we analyzed 343 patients treated within trials of the German… 
Highly Cited
2007
Highly Cited
2007
VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801.
PURPOSE Our previous phase II trial for treating human T-lymphotropic virus type I-associated adult T-cell leukemia-lymphoma… 
Highly Cited
2006
Highly Cited
2006
Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized…
We evaluated the role of rituximab (R) both in remission induction and maintenance treatment of relapsed/resistant follicular… 
Highly Cited
2005
Highly Cited
2005
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
PURPOSE To analyze the long-term outcome of patients included in the Lymphome Non Hodgkinien study 98-5 (LNH98-5) comparing… 
Highly Cited
2003
Highly Cited
2003
Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).
In diffuse large B-cell lymphoma (DLBCL), the combination of rituximab and CHOP (cyclophosphamide, doxorubicine, vincristine… 
Highly Cited
2000
Highly Cited
2000
CopA: An Escherichia coli Cu(I)-translocating P-type ATPase.
The copA gene product, a putative copper-translocating P-type ATPase, has been shown to be involved in copper resistance in… 
Highly Cited
1991
Highly Cited
1991
Copper resistance in Pseudomonas syringae mediated by periplasmic and outer membrane proteins.
  • J. Cha, D. Cooksey
  • Proceedings of the National Academy of Sciences…
  • 1991
  • Corpus ID: 38086653
Copper-resistant strains of Pseudomonas syringae pathovar tomato accumulate copper and develop blue colonies on copper-containing… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License